Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC clinical trial of a disulfide small ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

The COMPASSION-16 trial by Xiaohua Wu and colleagues addresses a crucial need in the management of advanced cervical cancer by evaluating cadonilimab, a novel bispecific antibody targeting PD-1 and ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

Leishmaniasis is a parasitic disease that affects up to 1 million people worldwide each year. It is caused by the protozoan ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...

NovoCure faces margin pressure, slow launches, and adoption hurdles beyond GBM, despite revenue beats and pipeline hopes.

GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC). The ...

In a world of quick wins and impatient headlines, Martin Goebel is playing the long game. Now Director for Mexico at ...

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or ...